To: PoorOpinion who wrote (1540 ) 3/31/2016 6:20:58 PM From: Dave@SI Read Replies (2) | Respond to PO, HiJW: The cash-on-hand figure is from our Q2/15 financials, filed with SEDAR. We believe we have enough capital on hand to initiate and get into our upcoming clinical study. We're an early clinical-stage biotech company. We obviously need to raise additional capital to reach our milestones, particularly as we get into larger and larger clinical studies. I'm a fundamentalist in terms of driving business, and I have reached critical milestones on less than a bootstrap in one of my prior companies, which was eventually acquired. I believe that if we can focus and execute, which we are doing, our valuation will increase, and we will raise additional capital through traditional means. We will rely on equity financing and would strongly consider nondilutive financing. Once we begin the clinical study, we would be eligible for nondilutive California Institute of Regenerative Medicine (CIRM) funding. The U.S. National Institutes of Health provides Phase 2 SBIR (Small Business Innovation Research) grants, which can provide significant nondilutive funding. Of course, partnerships are another option. The deal flow is heavy in this space. We would consider, under the right terms, co-development or any sort of partnership deal with an immuno-oncology-focused big pharma or big biotech company. youtube.com , note we (Scancell) were a bit unknown in US but finally got some attention in the US, from about 27:40 see mention of Keith Flaherty/Sloan Kettering.
